Fueling bold approaches

Flu Lab's mission is to eliminate the threat of influenza, a highly contagious virus that causes annual epidemics of disease and poses an ever-present risk of a catastrophic pandemic. To achieve this, Flu Lab finds and supports efforts that approach persistent problems in new and dynamic ways, with actionable results.

Through grantmaking, investing, and partner collaborations, Flu Lab seeks to help grantees and early-stage companies develop innovations that will help accelerate the availability of new solutions for global influenza challenges.

Awarded Grants and Investments

We are pleased to showcase current and past grantees and investments. For news and updates about our grants and investments, visit News + More.


Center for Green Schools

Equips schools and education stakeholders with information and guidance to improve ventilation and air filtration in classrooms.

$955,710 / May 2024, October 2021, August 2021

Scout LogoTM_Black.png


To advance the development of Respiratory Scout, a low-cost molecular test to diagnose influenza and other respiratory virus infections.

$161,000 / March 2024


University of Michigan

Establishing FluGuardians, a new birth cohort study to gain a deeper understanding of the development of influenza immunity.

$6,663,637 / March 2024

CRR new logo (1).png

Center for Radiological Research

  • Conducting far-UVC light ocular and stratum corneum safety studies in diverse human populations.

  • $1,662,490 / March 2024

Vivaldi Biosciences press release

Vivaldi Biosciences

Evaluating the immunogenicity and protection of an intranasal universal influenza vaccine candidate against wild-type transmission in ferrets.

$406,000 / December 2023


Washington University in St. Louis

Creating a handheld, rapid result, breath-based diagnostic for the detection of multiple respiratory pathogens.

$3,595,280 / November 2023


Panoplia Labs

Developing inhalable, broad-spectrum antivirals that provide extended prophylaxis against infectious diseases.

$159,000 / October 2023



Creating the first universal testing platform to provide fast, accurate, digital imaging-based identification for infectious disease pathogens.

Seed / October 2023

Versatope.Engineering Immunity-2.png


Investigating, in ferrets against H3N2, the sterilizing immunity potential of an intranasal universal influenza vaccine construct.

$59,215 / July 2023


Fishell Institute for Biomedical Devices

  • Adapting graphene-based biosensors for the selective detection of influenza.

  • $1,348,454 / June 2023


Emory University

Establishing a reproducible, experimental human infection model of influenza virus transmission and evaluating interventions.

$3,479,305 / March 2023


University of Oxford

Evaluating treatments for severe and complicated influenza infections in hospitalized patients with RECOVERY FLU, a cost-efficient, adaptive platform clinical trial.

£11,416,263 / December 2022


Kansas State University and Icahn School of Medicine

Establishing a swine herd model for assessing the efficacy of broadly protective influenza virus vaccines.

$1,652,929 / December 2022


University of Auckland

Leads a multidisciplinary and collaborative effort to observe and examine the reintroduction and transmission of influenza in New Zealand and identify novel immunological markers to inform influenza vaccine development.

11,340,572 NZD / December 2022, May 2021



Developing fast, accurate, and affordable molecular tests for routine use by everyone, including consumers in the home, employees in the workplace, and students at school.

Series C / November 2022, Series B / April 2021

RM + AUH UK logo ver2.jpg

Aarhus University Hospital

Leads INVITED, a multicenter, prospective randomized clinical trial among Type 1 diabetes patients to improve our understanding of the protective effect of influenza vaccination.

2,382,555 DKK / October 2022

Protas_Logo_900_x_450px copy.jpg


Reducing barriers to better treatments by designing and delivering high-quality, large-scale and global clinical trials at a fraction of current industry cost.

£5,000,000 / October 2022


NYC Virus Hunters

Creates an immersive approach to science education to unlock the potential of the next generation of influenza researchers in New York City.

$1,146,303 / July 2022, April 2020

Univ. of PA.png

Behavior Change for Good Initiative

Leverages the expertise of over 100 behavioral scientists to identify effective, scalable interventions for promoting immunizations.

$2,435,763 / March 2022, June 2021, October 2020


Virgina Tech

Leads the Multidisciplinary InvesTIGAtion of Transmission to Ease inFLUenza (MITIGATE FLU) study to transform our understanding of influenza virus transmission.

$8,792,291 / February 2022


Western Cooling Efficiency Center

Optimizing ventilation system operations to minimize airborne infectious disease transmission, pollutant exposure, and energy consumption.

$327,539 / November 2021


Center for Open Science

Leads multiple initiatives to promote open science and expand the publication of null and negative influenza research findings and replication studies.

$18,398,983 / August 2021, April 2020, August 2019


Influenzer Initiative

Brings diverse thinkers and disciplines together to identify big ideas and promote pathways to accelerating universal influenza vaccine development.

$8,900,000 / June 2021, January 2018


University of Cambridge

Pursuing a novel, host-directed approach to a universal influenza vaccine.

$904,384 / June 2021


Association of Immunization Managers

Brought together immunization managers and school nurses to identify replicable best practices for school-located vaccination programs.

$208,035 / June 2021


The Grand Challenge for Universal Influenza Vaccine Development

Supports eight teams developing novel, transformative approaches to universal influenza vaccines (in partnership with the Bill & Melinda Gates Foundation)

$6,215,453 / April 2021, January 2021, August 2019


Public Health Aerobiology, Virology, and Exhaled Biomarker Lab

Leads a research agenda centered on influenza transmission and the interplay between influenza and SARS-CoV-2 viruses.

$2,539,000 / March 2021


Sentinel Project

Develops ultra-sensitive genomic and CRISPR technologies to detect pathogens in multiple, connected settings to prevent pandemics before they start.

$5,000,000 / February 2021

African center.jpg

Sentinel Project

Combines diagnostic technology and information-sharing platforms to connect early warning data to the public health community.

$11,250,000 / December 2020


Imperial College London and Princeton University

Assessing performance characteristics and market dynamics of universal influenza vaccines using mathematical modeling methods.

$381,199 / November 2020


Stanford Healthcare Innovation Lab

Demonstrated the utility of wearables for early disease signaling, before symptoms emerge.

$1,870,000 / October 2020, August 2020


Outbreaks Near Me

Provides a crowdsourced infectious disease surveillance system to provide early outbreak warnings for communities and local public health agencies.

$1,005,451 / August 2020



Developed and examined a novel strategy for disease surveillance that improves representativeness of population samples.

$230,000 / August 2020


Berkeley, Public Health

Evaluated the direct and indirect health impacts of a school-based seasonal influenza vaccination program in the Bay Area.

$278,422 / August 2020, February 2020, February 2019


Community Epidemiology in Action

Created an open source, anonymous, privacy-first symptom sharing and exposure alerting application to help communities of close contacts protect themselves.

$100,000 / May 2020


Greenlight Biosciences

Offers an inexpensive, self-contained, and scalable mRNA manufacturing platform for vaccines targeting infectious diseases, including influenza and COVID-19.

Special purpose funding round / May 2020 (Exited)

Funding Opportunities

Flu Lab promotes innovation to speed the advancement of technologies and approaches for influenza, and we are open to receiving unsolicited pre-proposals at info@theflulab.org.